63132-39-8

Basic information

• Product Name: Olpadronate Sodium
• Synonyms: Olpadronate Sodium;Olpadronate;Olpadronic;olpadronic acid;3-(DiMethylaMino)-1-hydroxypropylidene-1,1-bisphosphonic Acid;3-DiMethylaMino-1-hydroxypropylidenebiphosphonic Acid;P,P'-[3-(DiMethylaMino)-1-hydroxypropylidene]bisphosphonic Acid
• CAS NO: 63132-39-8
• Molecular Formula: C5H15NO7P2
• Molecular Weight: 263.121
• Product Categories: Amines;Intermediates & Fine Chemicals;Pharmaceuticals;Phosphorylating and Phosphitylating Agents
• Mol File: 63132-39-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 590.1 °C at 760 mmHg
• Flash Point: 310.7 °C
• Appearance: /
• Density: 1.706 g/cm³
• Vapor Pressure: 2.21E-16mmHg at 25°C
• Refractive Index: 1.566
• PKA: 1.46±0.10(Predicted)
• CAS DataBase Reference: Olpadronate Sodium(CAS DataBase Reference)
• NIST Chemistry Reference: Olpadronate Sodium(63132-39-8)
• EPA Substance Registry System: Olpadronate Sodium(63132-39-8)

Safety Data

• Hazardous Substances Data: 63132-39-8(Hazardous Substances Data)

Usage

Description

Olpadronate Sodium, also known as Olpadronic acid, is a bisphosphonic acid derivative with potential applications in the medical field, particularly for the treatment of osteoporosis. It exhibits properties that can help in the management and prevention of bone loss, making it a promising candidate for pharmaceutical development.

Uses

Used in Pharmaceutical Industry:
Olpadronate Sodium is used as an anti-osteoporosis agent for its ability to inhibit bone resorption and promote bone mineralization. This helps in the treatment and management of osteoporosis, a condition characterized by reduced bone mass and increased risk of fractures.
Additionally, Olpadronate Sodium can be used in the preparation of bisphosphonic acid derivatives, which may have further applications in the medical field for bone-related disorders and conditions.

InChI:InChI=1/C5H15NO7P2/c1-6(2)4-3-5(7,14(8,9)10)15(11,12)13/h7H,3-4H2,1-2H3,(H2,8,9,10)(H2,11,12,13)

Upstream product

• 6300-04-5 3-dimethylaminopropionic acid 
• 50-00-0 formaldehyd 
• 40391-99-9 pamidronate 
• 63132-38-7 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid 
• 1738-25-6 3-dimethylaminopropiononitrile 

Relevant articles and documents

Preparation and application of sulfonic acid-phosphonic acid ligands

The invention relates to preparation and application of a sulfonic acid-phosphonic acid ligand. The structure of the sulfonic acid-phosphonic acid ligand comprises sulfonic acid, quaternary ammonium and phosphonic acid groups, and specifically comprises a sulfonic acid betaine-phosphonic acid ligand, a sulfonic acid-zoledronic acid ligand and a sulfonic acid-risedronic acid ligand. The molecular formula of the sulfobetaine-phosphonic acid ligand is C8H21NO10P2S, and the molecular weight of the sulfobetaine-phosphonic acid ligand is 384.2. The molecular formula of the sulfonic acid-zoledronic acid ligand is C8H16O10N2P2S, and the molecular weight of the sulfonic acid-zoledronic acid ligand is 394.23. The molecular formula of the sulfonic acid-risedronate ligand is C10H17O10NP2S, and the molecular weight of the sulfonic acid-risedronate ligand is 405.25. The sulfonic acid-phosphonic acid ligand disclosed by the invention has excellent hydrophilicity and can be coordinated with various metal elements. The molecules have important applications in the following two aspects: 1, the sulfonic acid-phosphonic acid ligand is used for modifying a hydrophobic nano material, so that the hydrophilicity of the material is remarkably improved, and the sulfonic acid-phosphonic acid ligand can be dispersed in a water phase; and 2, a certain inhibition effect is achieved on tumors.

Enteric coated formulation for bisphosphonic acids and salts thereof

Pharmaceutical compositions, processes for preparing the compositions and methods of using the composition are provided. The pharmaceutical composition comprises an inert core surrounded by an active coating containing one or more bisphosphonic acids or salts thereof, a seal coating surrounding the active coating and an enteric coating surrounding the seal coating. Alendronic acid and alendronate sodium trihydrate are the preferred active ingredients. The composition may be provided in the form of pellets in a capsule or Peltabs. The invention further provides methods for the treatment of disorders caused by the abnormal dissolution or deposition of calcium salts using the inventive compositions.

Formulation for treatment of osteoporosis

The present invention provides pharmaceutical formulations comprising at least one bisphosphonate and an absorption enhancing agent essentially consisting of a medium chain glyceride or a mixture of medium chain glycerides. The said pharmaceutical formulations are useful for the inhibition of bone resorption and for the treatment and prevention of osteoporosis.